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Abstract: Melanoma is the deadliest form of skin cancer and one of few cancers with a growing
incidence. A thorough understanding of its pathogenesis is fundamental to developing new strategies
to combat mortality and morbidity. Zebrafish—due in large part to their tractable genetics, conserved
pathways, and optical properties—have emerged as an excellent system to model melanoma. Zebrafish
have been used to study melanoma from a single tumor initiating cell, through metastasis, remission,
and finally into relapse. In this review, we examine seminal zebrafish studies that have advanced our
understanding of melanoma.
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1. Melanoma in Humans
Melanoma is a lethal malignancy of the melanocytes, cells that derive from the neural crest,
produce melanin, and are most commonly found in the skin. Melanoma accounts for only 1% of skin
cancer cases, but is responsible for most skin cancer deaths [1,2]. The World Health Organization
estimates that in 2018, 287,723 new cases of cutaneous melanoma were diagnosed and 60,712 patients
succumbed to their disease worldwide [2]. It is also estimated that there will be 4% more new diagnoses
of cutaneous melanoma in 2020 than in 2019, continuing the 47% rise seen over the last decade [1].
The vast majority of melanoma is caught early before it invades surrounding structures. These stage 1
and 2 melanomas have a 98% five-year survival rate. However, the survival rates drop precipitously
for stage 3 and 4 melanomas. Stage 4 melanomas, which are characterized by distant metastatic spread,
have an aggressive course of disease and poor prognosis [1].
In 2011, vemurafenib, a small molecule inhibitor that targets the most common mutation in
melanoma, B-Raf proto-oncogene, serine/threonine kinase (BRAFV600E), became the first drug since
interleukin (IL)-2 therapy to show improvement in treating melanoma [3–5]. Unfortunately, the majority
of patients on BRAF inhibitor monotherapy relapsed and died with little improvement in survival [5].
More recently, combination therapy trials revealed that patients positive for oncogenic BRAF mutations
treated with the BRAF inhibitor dabrafenib plus the dual specificity mitogen-activated protein kinase
kinase 1 (MAP2K1/MEK) inhibitor trametinib had improved survival [6]. Immunotherapies have
been pioneered in melanoma and have produced more durable remissions. The Checkmate 067 trial
investigated the impact of treatment of metastatic melanoma with the cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) inhibitor ipilimumab alone, the programmed death-ligand 1 (PD-L1) inhibitor
nivolumab alone, and combination therapy [7]. The trial demonstrated superior survival outcomes for
combination immunotherapy vs. single immunotherapy. At the five-year mark, 52% of patients on
combination ipilimumab/nivolumab were still alive (44% for nivolumab alone and 26% for ipilimumab
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alone) [7]. These clinical trials demonstrated substantial improvements in patient outcomes compared
to a decade ago and are currently being extended to the adjuvant setting [8]. However, despite these
improvements, nearly half of patients still succumbed to disease in five years, and adverse side effects
were a substantial problem with combined immunotherapy. While the success of BRAF inhibitors
and immunotherapy in improving outcomes is encouraging, the high rates of resistance and relapse
underscore the need for further research.
Identifying the genetic, molecular, and cellular pathobiology of melanoma is fundamental to
improving our diagnostic tools and developing novel therapeutics. Over the last two decades zebrafish
have become an established model and an excellent platform for such studies. In this review, we will
detail seminal zebrafish studies that have advanced our understanding not only of melanomagenesis
and disease progression, but also provided the basis for therapeutic development.
2. Melanocytes in Zebrafish
Zebrafish were first introduced as a model organism nearly 40 years ago, primarily for their utility
in developmental biology research [9]. Over the past decade, zebrafish have become an important
model organism for studying disease and development. Zebrafish have been used to model disparate
disease processes from cancer to infection [10,11]. The range of organ systems in the zebrafish allows
for modeling diverse cancers, ranging from hematopoietic malignancies such as leukemia to solid
tumors such as melanoma [12,13].
Zebrafish melanocytes derive from the neural crest and differentiate into large, dendritic, melanized
cells. There are dermal melanocytes arranged in a series of lateral stripes, giving rise to their characteristic
namesake patterning (Figure 1A). Zebrafish also have scale-associated melanocytes which develop
from the neural crest and are prone to transformation in adult zebrafish melanoma models. Recently,
adult melanocyte stem cells (MSCs) were also identified in zebrafish [14]. This pool of stem cells is
admixed with mature melanocytes inside the melanocyte stripe. These stem cells respond to injury
by differentiating into mature melanocytes to reconstitute the skin’s pigment pattern or dividing
symmetrically to replenish the melanocyte stem cell pool. Whereas zebrafish melanocytes share
many features with human melanocytes, there are differences that may limit the use of zebrafish in
studying melanocyte and melanoma biology. Unlike their mammalian counterparts which impart
pigment-containing melanosomes to the surrounding keratinocytes, zebrafish melanocytes retain
their melanosomes. Additionally, the skin architecture and niches in which melanocytes and MSCs
reside is considerably different between species. Mammalian MSCs reside primarily in the bulge
region of the hair follicle, where they replenish melanocytes in the hair follicle bulb and the epidermis.
By contrast, stripe melanocytes in zebrafish are interspersed throughout the hypodermis without
apparent association to any anatomical niche [15].
In addition to their genetic tractability, zebrafish possess desirable optical properties. Zebrafish
embryos and larvae are transparent, allowing time-lapse imaging of developmental processes ex vivo.
Wild-type adult zebrafish are more opaque, although superficial cells such as melanocytes are readily
visualized. This superficial location, along with their melanin retention, allows precise assaying of
melanocyte cells at single-cell resolution in live animals.
The construction of the first zebrafish reference genome revealed that zebrafish contain 26,000
protein coding genes and 71.4% of human genes have an obvious zebrafish ortholog [16]. This percentage
is higher for human disease-related genes, with 82% of such genes having a zebrafish ortholog [16].
The pathways involved in zebrafish melanocyte biology are highly conserved. Zebrafish melanocyte
development is dependent on an MITF ortholog as a master regulator, KIT and other mitogen-activated
protein kinase (MAPK) signaling genes as important executors of cell fate, and a host of melanin
biosynthesis genes (including TYR, TYRP1, and PMEL) for differentiation. Loss of the zebrafish
orthologs of these genes results in phenotypes identical or similar to those found in mammals.
For instance, zebrafish with a mutation in tyrosinase fail to produce melanin, mirroring the mechanism
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for human albinism [17,18]. Conserved molecular and genetic pathways make zebrafish a suitable
model to study melanocyte biology and pathologies, including melanoma.
3. Modeling Melanoma Disease Drivers in Zebrafish
Activating mutations in BRAF, most commonly BRAFV600E, occur in nearly 50% of human
melanoma and lead to overactivation of the MAPK pathway [19]. However, these mutations alone
are not sufficient to give rise to malignancy, as human nevi frequently express BRAFV600E [20].
To test whether BRAFV600E could formally promote melanoma, Patton and colleagues expressed
human BRAFV600E under the melanocyte-specific mitfa promoter and found that zebrafish only
developed nevi [13]. However, injection into p53 loss-of-function mutants, p53(lf), gave rise to
tumors that histopathologically mirrored human melanomas [13]. Similarly, Dovey and colleagues
successfully modeled NRAS melanomas by introducing oncogenic NRASQ61K into p53(lf) animals [21].
While p53 itself is only mutated in 19% of human melanomas, most human melanomas lose p53
pathway function due to other mutational events, including frequent loss of the CDKN2A locus,
which encodes the ARF tumor suppressor, a regulator of p53 [22–26]. Additional models involving
less frequently mutated driver genes have been designed, including oncogenic HRAS-dependent
models [27–29]. Rarer melanoma subtypes have also been modeled in zebrafish. Uveal melanomas
are biologically distinct from their cutaneous counterparts and often contain driver mutations in
the G protein subunits GNAQ or GNA11 [30,31]. In 2016, Mouti and colleagues created the first
zebrafish model of uveal melanoma by driving the GNAQQ209P oncogene under the mitfa promoter in
a p53(lf) background [32]. They found that 33% of these Tg(mitfa:GNAQQ209P); p53(lf) animals go on to
develop uveal melanoma [32]. Based on similar genetics and histopathologic features, these zebrafish
melanomas are faithful representatives of human melanoma (Figure 1B–G).
Genomic features of zebrafish melanoma and their similarities to human melanoma have been
described. Zebrafish BRAF and NRAS-dependent melanomas do not display the same frequencies
of mutations as seen in sun-exposed human melanoma [33,34]. This is not unexpected, as human
melanomas retain a history of UV-induced mutations present in the cell of origin prior to transformation,
and such UV exposure is not present in zebrafish housing tanks. By contrast, the high degree of copy
number variation in human melanomas is also observed in zebrafish tumors [34–36]. Because of their
preponderance, it is likely that these copy number variations are important in the initiation and further
progression of zebrafish melanomas. In support of this possibility, many genes subject to copy number
variation in zebrafish melanoma are similarly varied in their copy number in human melanoma [36].
A high degree of copy number alterations may be a common feature of zebrafish tumor models, as
malignant peripheral nerve sheath tumors caused by loss of p53 also have frequent copy number
alterations [37].
The creation of these melanoma models has underscored the conserved nature of the pathway
activity changes between zebrafish and human melanomas. Consequently, zebrafish melanomas, based
on insights gained from patient sequencing results, serve as the platform to investigate additional
genetic and environmental melanoma modifiers of initiation, progression, metastasis and treatment.
4. Using Zebrafish to Discover Genetic Modifiers of Melanoma
These zebrafish melanoma models present the opportunity to investigate melanoma in a controlled
environment. In all these models, there is a cancerized field of cells with the same genetic alterations.
However, most cells will fail to give rise to tumors. Furthermore, even the cells that eventually become
tumors take many months to progress. This indicates the need for additional genetic or epigenetic
alterations for tumor formation and presents the opportunity for zebrafish tumorigenic models to
serve as poised backgrounds for the discovery of new melanoma modifier genes [38,39]. Some of
these modifiers are likely present in the many available genome sequences from patient melanomas.
However, melanomas have among the highest mutation burdens of any cancer [19,40–43], and most of
the detected mutations and copy number variations in human melanomas are likely to be passenger
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alterations. Using zebrafish as a screening platform, with its high throughput and tumorigenesis as a
readout, the few driver genes can potentially be discerned from the many passenger genes present in a
patient’s melanoma sequence.
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(D) Melanoma modifiers introduced into the Tg(mitfa:BRAFV600E); p53(lf) model using MiniCoopR (MCR)
resulted in aggressive melanomas, comparable to other models with alternative tumor drivers such as
NRAS proto-oncogene, GTPase (NRASQ61K) or HRas proto-oncogene, GTPase (HRASG12V) [21,27,36,45–48].
(E) Expression of HEXIM P-TEFb complex subunit 1 (HEXIM1) using MiniCoopR, or loss of growth
differentiation factor 6 alpha (gdf6a) in a Tg(mitfa:BRAFV600E);p53(lf) background led to delayed melanoma
onset [36,49]. (F) Ocular melanoma resulted from introduction of human G protein subunit alpha
q (GNAQQ209P) in a p53 loss-of-function background [32]. (G) Table of zebrafish melanoma model
components from A–F.
The first use of zebrafish to screen for novel genetic modifiers focused on recurrently amplified areas
of the human melanoma genome [46]. In this study, a ‘MiniCoopR’ screening strategy was developed
that utilized a strain in which a mitfa loss-of-function mutation was introduced into a tumor-prone
Tg(mitfa:BRAFV600E); p53(lf) background. The mitfa mutation abrogated melanocyte development
and melanoma formation. In Tg(mitfa:BRAFV600E); mitfa(lf); p53(lf) animals, a transgene containing
a wild-type mitfa gene was introduced from the MiniCoopR vector, thus rescuing melanocytes and
melanomas. This same vector also introduced a companion gene whose effects on tumor initiation and
progression could be measured in rescued animals. Among the companion genes screened were several
from recurrently amplified regions of the melanoma genome. One gene from a recurrently amplified
interval of chromosome 1q [50,51], SET domain bifurcated histone lysine methyltransferase 1 (SETDB1),
significantly accelerated melanoma onset. Mechanistic studies revealed that higher expression of
SETDB1 allowed melanocytes to escape senescence in response to oncogenic insult. Importantly,
immunohistochemistry of human tissues showed that SETDB1 protein was highly expressed in
melanomas as compared to benign nevi or normal melanocytes [46]. This discovery established a
powerful method for using zebrafish to identify potential oncogenes from genomic and transcriptional
changes present in human tumors.
Variations of the MiniCoopR strategy, described above, have been developed to screen for
melanoma modifiers. Recently, Ablain and colleagues utilized the MiniCoopR platform to identify a
tumor suppressor of mucosal melanoma. After sequencing human mucosal melanomas, they learned
that sprout related EVH1 domain containing 1 (SPRED1), a negative regulator of the MAPK pathway,
is inactivated in 37% of these tumors [52]. A modified version of the MiniCoopR approach was
developed to test the effect of SPRED1 loss on melanoma initiation [53]. This new system, termed
Mazerati, combined mitfa-dependent melanocyte rescue with Crispr/Cas9-mediated genome editing [53].
Zebrafish spred1 loss was found to accelerate melanoma onset in a KIT, but not BRAF or NRAS, oncogene
background. Since KIT mutations predominate over BRAF or NRAS mutations in mucosal melanomas,
this result suggests a special cooperativity between KIT gain of function and SPRED1 loss.
Melanoma genes have also been identified based on comparative genomic approaches. Venkatesan
and colleagues compared genes subject to copy number amplification in human melanomas to
those subject to copy number amplification in zebrafish melanomas [36]. This comparison revealed
that many syntenic genomic intervals, and the genes within these intervals, are amplified in both
species, suggesting an underlying mechanistic conservation of melanomagenesis. In MiniCoopR-based
screening of genes amplified in both species, the bone morphogenetic protein (BMP) ligand GDF6 (gdf6a
and gdf6b in zebrafish) was identified as a new melanoma oncogene. GDF6-dependent BMP signaling
was found to be critical for maintaining neural crest identity, and withdrawal of BMP signaling led
to differentiation and death of melanoma cells. The findings that GDF6-dependent BMP signaling is
observed in ~80% of patient tumors and its expression is correlated with patient survival imply that
this gene and signaling pathway are potential targets for anti-melanoma therapy.
The strategy of using zebrafish to functionally analyze genes highlighted by genomic and
transcriptomic studies of human tumors has also revealed novel insights into how melanomas cope
with nucleotide stress. Tan and colleagues utilized Oncomine expression data to evaluate the role of
candidate transcription elongation regulators in melanoma and found that HEXIM1 P-TEFb complex
subunit 1 (HEXIM1) expression was significantly reduced in melanomas compared to nevi [49,54].
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Consistent with the possibility that HEXIM1 acts as a tumor suppressor, elevated expression of this
gene using the MiniCoopR system delayed and Crispr/Cas9-mediated knockout accelerated melanoma
onset. Mechanistic studies pointed to a role in transcriptional elongation; HEXIM1 normally acts
through positive transcription elongation factor (p-TEFb) to inhibit transcription of tumor-promoting
genes and stabilize transcription of other tumor suppressor genes [55]. HEXIM1 expression itself is
regulated by nucleotide stress via the specificity protein 1 (SP1) transcription factor, thus linking the
state of nucleotide stores to tumorigenic potential.
The zebrafish model has uncovered the role of chromatin modifiers in melanoma. In 2017, Scahill
and colleagues found that loss of kdm2aa, an ortholog of the histone demethylase KDM2A, led to
the formation of spontaneous melanomas at high frequency [56]. These tumors arose independently
of BRAFV600E and other common driver mutations as well as common tumor suppressor losses.
Gene expression profiling showed a concerted response of genes related to translation, DNA replication,
and chromatin regulation upon knockdown of kdm2aa, suggesting a role for aberrant chromatin
methylation in melanomagenesis.
Zebrafish models have also been used to investigate genes and transcriptomic programs important
in melanoma progression. Salhi and colleagues compared expression and phosphorylation patterns of
tumorigenic pathways in human melanoma lines derived from radial (RGP) or vertical (VGP) growth
phase melanomas and discovered that ribosomal protein S6 kinase 1 (RSK1) is active in VGP but
not in RGP melanomas [57]. Subsequent cell culture assays revealed that inhibition of RSK1 led to
downregulation of a transcriptional program that supports cell motility. Constitutive activation of
RSK1 in zebrafish accelerated melanoma onset and promoted invasion, whereas inactivation of RSK1
delayed tumor initiation. This work provides further insight into the role of RSK1, which had been
previously identified as a downstream target of the MAPK pathway, in melanoma progression [58].
Further transcriptional analysis of aggressive RSK1-activated melanomas in zebrafish revealed
upregulation of genes involved in oxidative phosphorylation (OXPHOS) [59]. To investigate
this association between OXPHOS and melanoma, Salhi and colleagues stained human primary
melanoma samples for peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC1α),
the proposed master regulator of tumor OXPHOS [60,61]. They found a positive association between
PGC1α, primary melanoma thickness, and proliferative marker Ki-67, suggesting a role for PGC1α
in melanoma progression. Follow up in vitro knockdowns of PGC1α resulted in downregulation of
transcriptional signatures associated with melanoma progression. These results suggest a role for
PGC1α in melanoma progression via mediation of oxidative phosphorylation [59].
More recently, Henderson and colleagues compared the transcriptomes of advanced VGP
melanomas in zebrafish to early RGP melanomas and found that lipid metabolism was dysregulated in
more advanced tumors [62]. Elevated expression of one dysregulated gene, the lipoprotein lipase LPL,
accelerated melanoma onset in zebrafish. LPL has previously been implicated in tumor progression [63],
and results in zebrafish support the notion that lipid metabolism can regulate even the earliest stages
of tumor progression.
Taken together, the studies highlighted above underline the utility of zebrafish to screen
and discover novel melanoma genes, increasing our understanding of genetic factors that drive
patient outcomes.
5. Intersection of Melanocyte Development and Melanoma in Zebrafish
The microphthalmia-associated transcription factor (MITF) and KIT proto-oncogene, receptor tyrosine
kinase (c-KIT) were two of the first genes discovered to play a role in melanocyte biology [64–66]. In addition
to their conserved roles in development, both genes are implicated in melanoma pathogenesis [67–69].
These genes and the networks in which they function are well conserved, and studies in zebrafish have
helped to elucidate new roles in both melanocyte development and melanoma.
MITF is the master regulator of the melanocyte lineage [70]. Evidence for this role includes genetic
studies in mice and zebrafish as well as the pigmentary defects seen in MITF-mutant patients, who suffer
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from Waardenburg syndrome (type 2a). Waardenburg syndrome patients frequently display pigment
defects such as white forelock, skin hypopigmentation, and premature hair graying [71,72]. More severe
mutations have been isolated in mice and zebrafish, and MITF-null mutations in both species cause a
complete loss of melanocytes [73,74]. In melanomas, early genomic studies found that MITF was amplified
in metastatic disease and its increased expression correlated with decreased patient survival, suggesting
that MITF is an oncogene [67]. However, several studies have shown that decreased MITF can also be
pro-tumorigenic, indicating divergent roles for this gene in melanoma [75,76]. To address how different
levels of MITF activity could affect melanoma initiation and maintenance, Travnickova and colleagues
utilized a unique, temperature-sensitive allele of zebrafish mitfa. This allele, vc7, is hypomorphic at the
permissive temperature but completely inactive at the restrictive temperature [45,77]. They found that
mitfa(vc7); p53(lf) animals develop superficial melanomas enriched for stem and invasive gene signatures,
similar to what is observed in human MITF-low melanomas [48]. Further reduction of mitfa activity by
upshifting to the restrictive temperature led to near-total tumor regression. A small population of tumor
cells, akin to minimal residual disease (MRD), remained at the tumor site, and this population seeded
tumor relapse when mitfa activity was restored. This study indicates that MITF activity is important in
bulk tumor cells, but MRD is characterized by MITF inactivity, suggesting how differing levels of MITF
can support tumor maintenance and relapse.
The type 3 receptor tyrosine kinase KIT is required for normal melanocyte development in mammals
and zebrafish. In humans, heterozygous loss of the KIT gene results in piebaldism, a pigmentation
disorder characterized by a white forelock [78]. Mice deficient in Kit and its cognate ligand, stem cell factor
(SCF), develop a similar pigmentation phenotype of white spotting [66,79]. Zebrafish orthologs of KIT
and its ligand (kita and kitlga, respectively) are deficient in melanocytes due to their inappropriate death in
embryos and failure to develop in adults [80,81]. KIT gain-of-function mutations have been shown to
drive the formation of rare acral and mucosal melanoma subtypes [68,69]. By contrast, more common
cutaneous melanomas typically show loss of KIT expression [82,83]. The effect of KIT loss was investigated
in zebrafish by introducing a kita-null mutation into the Tg(mitfa:BRAFV600E); p53(lf) melanoma-prone
strain [84]. Loss of kita caused accelerated melanoma onset, with increased BRAFV600E-driven MAPK
pathway signaling evident in tumors. Mechanistic studies revealed that KIT engages wild-type BRAF,
which competes with BRAFV600E, thereby attenuating signaling flux through the MAPK pathway [84].
Studies with MITF and KIT take advantage of the conserved genetic, molecular, and cellular
behaviors of mammalian and zebrafish melanocytes, making zebrafish an excellent platform for
discovering new insights into melanocytes and their pathologies.
6. Zebrafish Neural Crest Reactivation in Melanoma Initiation and Progression
The neural crest is a highly migratory, multipotent embryonic cell population that gives rise to
diverse cell types including cutaneous melanocytes. Early transcriptional studies discovered that
aggressive melanoma cells have gene signatures, like those of neural crest cells, associated with
cellular plasticity, dedifferentiation and migration [85–88]. In vivo studies revealed that melanoma
cells transplanted into zebrafish embryos maintain a plastic, dedifferentiated, pro-migratory state [89].
Similarly, melanoma cells transplanted into chick embryos invaded along stereotypical neural crest
migratory pathways, suggesting these cells respond to neural crest microenvironmental signals [90].
Zebrafish models have been vital in understanding the importance and timing of this neural
crest gene program. In 2011, White and colleagues discovered that zebrafish melanomas reactivated
a developmental transcriptional signature highlighted by neural crest genes [91]. To determine if
these transcriptional changes were important for melanoma progression, a chemical genetic screen
was performed for small molecules capable of suppressing neural crest development in zebrafish
embryos. Dihydroorotate dehydrogenase inhibitors, including the FDA-approved drug leflunomide,
inhibited neural crest development via the reduction of pyrimidine reserves, resulting in pausing of
transcriptional elongation in genes required for neural crest development [91]. A mechanistic follow
up study utilized a chemical screen for the rescue of neural crest development following leflunomide
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treatment and identified the RNA helicase protein DExD-box helicase 21 (DDX21) as a sensor and
mediator of transcription during nucleotide stress [92]. Crucially, treatment with leflunomide caused
a decrease in melanoma cell growth in vitro, in addition to inhibiting the growth of autochthonous
zebrafish melanomas and xenografted melanomas in mice [91]. Clinical trials are currently testing the
effects of leflunomide in combination with other melanoma treatments such as MEK inhibitors [93].
In 2016, Kaufman and colleagues used a reporter for a key member of this neural crest signature,
the gene crestin, to show that it was expressed in early-stage melanomas [47]. Indeed, crestin expression
was observed in single cells of origin that would progress to form tumors. The crestin reporter thus
serves as a useful tool to track, in real time, the earliest stages of tumor initiation [47,94]. While there is
currently no known mammalian equivalent of crestin, this landmark discovery has given rise to new
research into the genetic and epigenetic mechanisms governing a neural crest state reactivation.
More recently, the crestin reporter has been utilized in a chemical genetic screen to identify
modulators of neural crest identity [95]. In this screen, caffeic acid phenethyl ester (CAPE) was found as
an inhibitor of zebrafish neural crest development. Mechanistically, CAPE interrupted sox10-mediated
neural crest formation via inhibition of the fibroblast growth factor-stimulated phosphoinositide
3-kinase/Ak strain transforming (PI3K/AKT) signaling axis [95]. This identification of PI3K/AKT
as a novel intracellular pathway regulating neural crest differentiation provides further targets for
manipulating neural crest identity in melanoma.
These zebrafish melanoma studies have revealed that a neural crest gene signature, marked by
crestin, is present in the earliest melanoma lesions and remains present through disease progression.
Importantly, utilizing high throughput drug screening of embryonic phenotypes, such as neural crest
development, has identified pathway inhibitors with potential anti-tumor properties [91,95]. This new
understanding of the importance and timing of melanoma’s neural crest identity coupled with high
throughput screening can enable accelerated discovery of novel melanoma therapeutics.
7. Utilizing Zebrafish to Understand the Melanoma Microenvironment
Melanoma lethality is due in part to its proclivity to progress and metastasize into difficult-to-treat
areas such as the lungs, brain and bone. Metastatic melanoma cells must migrate through complex
tissues, seed, and then survive in distant tissues. Understanding how other cells influence melanoma
initiation, progression, and metastasis is critically important for improving outcomes for melanoma
patients. The desirable optical properties of zebrafish coupled with plentiful tissue-specific reporters
allow for in vivo visualization of interactions between melanoma cells and their surrounding tissues,
thus enabling studies of the melanoma microenvironment.
7.1. Using Zebrafish to Study Phenotype Switching in Melanoma
During the metastatic process melanoma cells are thought to undergo phenotype switching,
in which a dedifferentiated, less proliferative and more motile phenotype is adopted to initiate
metastasis, and a more differentiated and proliferative phenotype is adopted to facilitate growth of
macrometastases upon seeding into distant tissues. To understand phenotype switching, Kim and
colleagues injected a zebrafish melanoma cell line, ZMEL1-GFP, into pigmentless “casper” zebrafish
to model melanoma metastasis [96,97]. Using this model, individual metastatic cells were tracked
and metastatic spread and growth quantified longitudinally [98]. Upon injection, ZMEL1-GFP cells,
which are unpigmented and mesenchymal in culture, became pigmented at the engraftment site.
Similarly, secondary metastases appeared unpigmented at first but soon became pigmented, suggesting
that signals at the site of metastasis were regulating a phenotype switch. Gene expression profiling
combined with in vitro screening revealed that the vasoactive endothelins (EDN)-1 and EDN-3 induced
differentiation and proliferation. Consistent with a role in promoting differentiation and proliferation
upon metastatic spread, ZMEL1-GFP secondary metastases in zebrafish mutant for edn3 and its
biosynthetic enzyme ece2b were smaller and less pigmented. This work uncovered a novel signaling
system governing phenotype switching in target tissues during melanoma metastasis (Figure 2A) [97].
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7.2. Using Zebrafish to Study Innate Immune Cells in Melanoma
Tissue-resident macrophages serve a variety of functions such as tissue remodeling, phagocytosis,
and antigen presentation. Macrophages are also present in tumors where their functions are less
understood. To investigate the role of macrophages in melanoma, Roh-Johnson and colleagues
transplanted melanoma cells into larval zebrafish and monitored tumor–immune cell interactions [99].
Surprisingly, microscopy revealed that GFP-labeled melanoma cells transferred a portion of their
cytoplasm to the macrophages, and this cytoplasmic transfer correlated with melanoma cell
dissemination. Follow-up studies revealed that blocking macrophage recruitment to transplanted
melanoma cells decreased tumor cell dissemination, indicating that this melanoma–macrophage
cytoplasmic transfer is functionally important to metastatic progression (Figure 2B).
Macrophages also play key roles in inflammation and cancer [100]. Recently, Gómez-Abenza and
colleagues discovered that serine peptidase inhibitor, Kunitz type 1 (SPINT1) regulated melanoma
aggression and crosstalk in the tumor microenvironment [101]. They noted that a subset of melanoma
patients had high levels of SPINT1 mRNA, and this upregulation correlated with poor prognosis and
greater tumor-associated macrophage infiltration. Furthermore, more aggressive melanomas were
observed in a SPINT1-deficient background in zebrafish, suggesting that SPINT1 deficiency accelerates
melanoma formation via altered immune cell recruitment and activity [101].
7.3. Using Zebrafish to Study Vascular Cells in Melanoma
Angiogenesis is a critical step in the progression of microtumors. In zebrafish, the growth of new
tumor vasculature has been studied by injecting melanoma cells into the perivitelline space of embryos
and observing the recruitment and growth of fluorescently-labeled vasculature [102]. More recent
mechanistic studies have investigated signals that regulate angiogenic growth [103,104]. In addition to
vascular endothelial growth factor (VEGF)-mediated signaling, it was shown that vasculature-derived
IL-8 could signal through the C-X-C motif chemokine receptor 2 (CXCR2) receptor in melanoma cells
to promote angiogenesis. Taken together, these studies highlight the mechanisms of cell–cell signaling
between melanomas and vasculature to promote melanomagenesis (Figure 2C).
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3/erb-b2 receptor tyrosine kinase (EDN3/ERBB) signaling promoted differentiation and proliferation
upon metastasis [97]. (B) Melanoma cell cytoplasmic transfer to macrophages promoted melanoma
progression [99]. (C) Interleukin 8/C-X-C motif chemokine receptor 2 (IL-8/CXCR2) signaling
encouraged melanoma progression [103,104]. (D) Melanoma cells cupped vasculature to migrate
and metastasize [105]. (E) Adipocytes contributed fatty acids to melanoma cells during melanoma
progression [106].
To model the migratory potential of melanoma cells, Fornabaio and colleagues injected GFP-labeled
cutaneous melanoma cells and non-malignant melanocytes into larval zebrafish yolk sacs and monitored
their survival and migration [105]. Strikingly, the melanoma cells migrated outside of the yolk sac
while the non-malignant cells either died or remained in the yolk sac. Time lapse imaging coupled
with 3D reconstruction revealed these migrating melanoma cells changed their morphology to extend
pseudopods and cup the external surface of blood vessels [105]. Uveal melanoma cell lines revealed a
similar angiotropism, demonstrating that cutaneous and uveal melanomas can utilize vasculature as
tracts for migration and metastasis even without intravasation (Figure 2D).
7.4. Using Zebrafish to Study Adipocytes in Melanoma
As melanoma advances, it typically grows through adipocyte-rich subcutaneous tissue, introducing
a new microenvironment and different cell–cell interactions. Recently, Zhang and colleagues used
a combination of mouse and zebrafish models to investigate how adipocytes promote melanoma
progression. They found that adipocytes in the melanoma microenvironment transferred fatty acids
to melanocytes via fatty acid transport protein 1 (FATP1) transporters expressed on the surface of
melanoma cells [106]. Furthermore, elevated expression of FATP1 expression in melanocytes accelerated
BRAFV600E-driven melanoma development in both zebrafish and murine models. This work highlighted
the utility of zebrafish and murine models to uncover complex melanoma microenvironmental
interactions promoting the progression of melanoma.
The melanoma microenvironment is complex, dynamic, and diverse. Melanoma utilizes or
interrupts signals from surrounding fibroblasts, vasculature, immune cells, adipocytes and other
cell types in order to survive, proliferate and invade. With several autochthonous models in which
tumor-microenvironment interactions can be measured and manipulated, studies in zebrafish are
likely to further expand our understanding of how the microenvironment encourages the initiation,
progression and metastasis of melanoma.
8. Future Directions
While treatments for late-stage melanoma have greatly improved in the last decade, significant
challenges remain in elucidating disease and drug resistance mechanisms and translating these findings
to a clinical environment to benefit patients who respond poorly to current therapies. This group of
poor responders is evidenced by the nearly 50% of metastatic melanoma patients who still die within
five years of diagnosis [6,7]. Zebrafish models have provided, and can continue to provide, unique
insights into pathogenesis and treatment.
8.1. Understanding the Micro- and Macro-Environmental Factors that Encourage Disease Initiation,
Progression, Metastasis and Relapse
Deeper knowledge of how the melanoma microenvironment influences disease progression
will yield crucial understandings in how to target melanoma. The impacts of understanding these
interactions are clinically important with recent advances in immunotherapy. The zebrafish has innate
and adaptive immune systems, the latter replete with B-cells, T-cells, regulatory T-cells, and other
cell subpopulations [107–110]. In addition, zebrafish melanomas form, much like early-stage human
tumors, in apposition to keratinocytes, fibroblasts, resident immune cells, vasculature, and adipocytes.
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This juxtaposition of cell types and ability to perform intravital imaging open many opportunities for
melanoma studies in zebrafish. Similarly, zebrafish can be used to assay broad macroenvironmental
choices and their impact on oncogenesis. For instance, by monitoring crestin:EGFP patches in a
Tg(mitfa:BRAFV600E);p53(lf) strain, Grigura and colleagues observed that feeding amount significantly
alters tumor onset [111]. Further understanding of the extrinsic factors driving melanoma will be vital
to understanding how to prevent and treat metastatic disease.
8.2. Understanding the Role of Developmental Mechanisms in Melanoma Pathogenesis
In addition to insights gained by studying the tumor microenvironment, studies of melanocyte
development can inform mechanisms that may be involved in melanoma pathogenesis. Complementing
the discovery that GDF6-activated BMP signaling suppresses differentiation to promote invasive
melanoma, Gramann and colleagues found that loss of the zebrafish ortholog gdf6a in development
leads to an excess of melanocytes specified from the neural crest [112]. Similarly, Lister and colleagues
demonstrated that MITF levels, which they directly controlled with the temperature-sensitive
hypomorphic mitfa(vc7) allele, are critical to melanocyte development and regeneration in addition
to the role in melanoma described above [45]. Understanding the role of these genes in melanocyte
development provides insight into their mechanisms of action and suitability as melanoma
therapeutic targets.
8.3. Utilizing Zebrafish Xenografts to Model Patient Disease
Zebrafish xenografts have been, and continue to be, a critical tool in understanding
melanomagenesis [88,89,113,114]. During embryogenesis, hundreds of cells can be engrafted in
the absence of an adaptive immune system [115]. Their transparency and many available transgenic
reporters make zebrafish embryos an excellent system for performing xenografts. Furthermore,
the small size of zebrafish embryos enables high-throughput screens of potential therapeutics. However,
this small size also hinders the use of zebrafish embryos in studying heterogenous bulk tumors or
invasion of melanoma cells into mature organs. There is also a temperature incompatibility between
zebrafish embryos, which grow at a maximum of 35 ◦C, and patient derived xenografts (PDXs), which
grow at 37 ◦C.
Adult zebrafish hosts have been used to overcome limitations of embryo xenografts. Irradiated
adults have been used as hosts, but the recovery of adaptive immunity approximately three weeks after
irradiation leads to death of engrafted cells, preventing long-term engraftment [113,116]. More recently,
genetic immune cell knockouts grown at 37 ◦C were successfully developed and used to test therapeutic
efficacy [117–119]. These zebrafish allow for long-term engraftment of patient derived samples. Now,
in a clinically relevant timeframe, a patient’s melanoma could be engrafted, expanded, and tested
with various therapies, helping to anticipate drug resistance patterns and revealing the best course of
treatment for the patient. These new zebrafish PDXs can serve as a suitable complement to conventional
mouse PDXs, offering time savings and higher throughput. These recent developments provide a
unique opportunity to provide a direct clinical correlate of therapy.
8.4. Utilizing Zebrafish as a Screening Platform
Zebrafish have been used extensively for large-scale and targeted drug screens [92,120–123].
Their high fecundity and simple water-borne drug administration provide an ideal platform
for high-throughput screening of drug panels. Additionally, their optical features, plentiful
tissue-specific reporters, and conserved developmental and disease programs make phenotypic
readouts straightforward and findings applicable to other species. Combinations of these tools and
features has and will facilitate the discovery of novel melanoma therapeutics from existing drug
libraries. For instance, a recent screen for drugs that abrogated the development of excess melanocytes in
kita:HRAS embryos identified clotrimazole as a potential novel melanoma therapeutic [121]. Extending
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these screens to a setting with tumors as a direct readout is a beneficial next step, one that would
greatly facilitate the identification of therapeutic lead compounds.
9. Conclusions
While significant progress has been made in the treatment of melanoma, advanced melanoma
is still a devasting disease with poor outcomes. Zebrafish offer an excellent system for modeling
melanocyte and melanoma biology. Recent advancements in the multifactorial determinants of
melanoma, coupled with advances in genome editing and other technologies, present even greater
opportunities to model melanoma and develop future therapeutics in this model system.
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